Autolus Limited

Immunoqure Ag

Ucl Business Plc

Shimobi Onuoha

Shaun Cordoba

Simon Thomas

Martin Pulé

Matteo Righi

Mathieu Ferrari

Annalisa Macagno

Adrian Hayday

Kai Krohn

Kai Kisand

James Sillibourne

Wen Chean Lim

Biao Ma

Annamari Ranki

Part Peterson

Edward Stuart

Ram Jha

Evangelia Kokalaki

Mike Rothe

Paert Peterson

Martin Woodward

Syeda F Y Haque

Paul Maciocia

Alexander Kinna

Marco Della Peruta

Maria Stavrou

Vania Baldan

Anna Bulek

Meggan Czapiga

Ana Margarida Neves

Pärt Peterson

Evangelina Kokalaki

Martin Pule

ANTI TRBC1 ANTIGEN BINDING DOMAINS

Antigen-Binding Domain

The present invention provides a chimeric antigen receptor (CAR) which binds a low density target antigen, which comprises a Fab antigen binding domain. The invention also relates to cells expressing such a CAR and their use in the treatment of disease.

Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors

The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.

Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface

The present invention provides a variant antigen-binding domain which comprises at least one mutation in the VH domain compared to a reference antibody and which displays an increased affinity for TRBC2 over the reference antibody. It further provides an antibody, a chimeric antigen receptor (CAR), and a bispecific T-cell engager (BiTE), a cell which comprises said CAR, and a conjugate comprising said variant antigen-binding domain or said antibody. Additionally, it provides medical uses, diagnostic methods and methods of personalised medicine that exploit the products of the invention.

Binding domain

The present invention provides a chimeric antigen receptor (CAR) which specifically binds CD79 as well as a nucleic acid sequence and a vector encoding the CAR. It further provides a cell which expresses the CAR at the cell surface.

CD79-specific chimeric antigen receptor

The invention relates to a method of determining the T cell receptor β chain (TRBC) gene type of a cell, the method comprising (a) determining the J gene type expressed in said cell, and (b) inferring from (a) the TRBC gene type expressed in said cell. The invention further relates to use of a CAR T cell targeted to a T cell receptor β chain (TRBC) type 1, or a CAR T cell targeted to a T cell receptor β chain (TRBC) type 2. The invention further relates to a method of medical treatment, and to nucleic acid probes.

Molecular assessment of TRBC usage

The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.

Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof

The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.

Cell

Chimeric antigen receptor

The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.

The present invention provides antibodies and polyclonal antibody preparations which bind the intracellular portion of either T-cell receptor constant region 2 (TRBC2) or T-cell receptor constant region 1 (TRBC1). The antibodies can be used to determine whether a T-cell malignancy clonally expresses TRBC1 or TRBC2.

T-cell receptor constant region 1 antibody or T-cell receptor constant region 2 antibody

The present invention provides a chimeric polypeptide comprising: an antigen-binding domain which constitutively binds to an ectodomain of a first chain of a cytokine receptor; a transmembrane domain; and an endodomain from a second chain of the cytokine receptor which chimeric polypeptide, when expressed in a cell, binds to the endogenous first chain of the cytokine receptor causing constitutive cytokine signalling.

Polypeptide

Growing community of inventors

London, United Kingdom

Shimobi Onuoha